SpringWorks Therapeutics, Inc. - common stock (SWTX)
51.38
-1.90 (-3.57%)
Springworks Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for underserved patient populations, particularly in the field of rare diseases and oncology
The company utilizes its proprietary drug development platform to identify and advance novel treatments, focusing on precision medicine approaches. By leveraging its expertise in biomarker-driven strategies, Springworks aims to bring transformative therapeutics to market, addressing significant unmet medical needs and improving the quality of life for patients dealing with complex health challenges.
SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.
Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.
SWTX stock results show that SpringWorks Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
